Jounce Therapeutics (NASDAQ: JNCE) June call option implied volatility is at 141, July is at 101; compared to its 52-week range of 62 to 186 into announcing data from its ongoing Phase 1/2 ICONIC trial, an adaptive design, open label trial evaluating JTX-2011 monotherapy and in combination with nivolumab, will be the subject of an oral presentation at the upcoming 2018 American Society of Clinical Oncology, or ASCO, annual meeting.